OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conference

Impact · against what's priced in

OABI introduces a new hardware-based revenue stream with the xPloration instrument and identifies specific clinical catalysts for 2027. While the massive milestone pipeline and cash position are likely already reflected in the valuation, the transition toward a consumables-based model and imminent partner data provide fresh catalysts.

OABI+0.30

No priced-in read yet